{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:22:47Z","timestamp":1791595367334,"version":"4.3.4"},"reference-count":54,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T00:00:00Z","timestamp":1359590400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0055818","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T22:00:17Z","timestamp":1359669617000},"page":"e55818","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":124,"title":["Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1\/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia"],"prefix":"10.1371","volume":"8","author":[{"given":"Lisa","family":"Christiansson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"S\u00f6derlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Simonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Olsson-Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica S. I.","family":"Loskog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,1,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"JD Rowley","year":"1973","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"JE Sokal","year":"1984","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"A Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"MM Horowitz","year":"1990","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2002-02-0535","article-title":"Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase","volume":"101","author":"R Or","year":"2003","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"FX Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-{alpha}2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia","volume":"118","author":"B Simonsson","year":"2011","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1158\/1078-0432.CCR-05-0250","article-title":"Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia","volume":"11","author":"Z Li","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia","volume":"29","author":"R Hehlmann","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"C Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4049\/jimmunol.166.1.678","article-title":"Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer","volume":"166","author":"B Almand","year":"2001","journal-title":"J Immunol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1158\/0008-5472.CAN-09-3767","article-title":"Immature immunosuppressive CD14+HLA-DR-\/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign","volume":"70","author":"I Poschke","year":"2010","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"8270","DOI":"10.1158\/1078-0432.CCR-08-0165","article-title":"Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma","volume":"14","author":"S Kusmartsev","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/neuonc\/nor042","article-title":"Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma","volume":"13","author":"B Raychaudhuri","year":"2011","journal-title":"Neuro Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4049\/jimmunol.172.2.989","article-title":"Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species","volume":"172","author":"S Kusmartsev","year":"2004","journal-title":"J Immunol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S1471-4906(03)00132-7","article-title":"L-arginine metabolism in myeloid cells controls T-lymphocyte functions","volume":"24","author":"V Bronte","year":"2003","journal-title":"Trends Immunol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2006-06-031856","article-title":"L-arginine availability regulates T-lymphocyte cell-cycle progression","volume":"109","author":"PC Rodriguez","year":"2007","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.imlet.2007.11.012","article-title":"Immunosuppressive mechanisms in human tumors: why we still cannot cure cancer","volume":"116","author":"S Gross","year":"2008","journal-title":"Immunol Lett"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"7553","DOI":"10.4049\/jimmunol.180.11.7553","article-title":"PDL-1 blockade impedes T cell expansion and protective immunity primed by attenuated Listeria monocytogenes","volume":"180","author":"JH Rowe","year":"2008","journal-title":"J Immunol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression","volume":"114","author":"S Mumprecht","year":"2009","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2567.2010.03308.x","article-title":"T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies","volume":"131","author":"CA Lindqvist","year":"2010","journal-title":"Immunology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.4049\/jimmunol.135.5.3172","article-title":"Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro","volume":"135","author":"LA Rubin","year":"1985","journal-title":"J Immunol"},{"key":"ref23","first-page":"752","article-title":"Tumor burden and serum level of soluble CD25, CD8, CD23, CD54 and CD44 in non-Hodgkin&apos;s lymphoma","volume":"83","author":"M Perez-Encinas","year":"1998","journal-title":"Haematologica"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/leu.2009.190","article-title":"Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy","volume":"24","author":"S Mustjoki","year":"2010","journal-title":"Leukemia"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"J Hasford","year":"2011","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.3748\/wjg.v18.i38.5454","article-title":"Correlation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer","volume":"18","author":"ZJ Jiao","year":"2012","journal-title":"World J Gastroenterol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00277-012-1427-0","article-title":"Nitric oxide metabolites and arginase I levels in beta-thalassemic patients: an Egyptian study","volume":"91","author":"SB El-Hady","year":"2012","journal-title":"Ann Hematol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3109\/0886022X.2012.713297","article-title":"Plasma indoleamine 2,3-dioxygenase and arginase type I may contribute to decreased blood T-cell count in hemodialysis patients","volume":"34","author":"T Eleftheriadis","year":"2012","journal-title":"Ren Fail"},{"key":"ref29","article-title":"Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13","author":"RF Gabitass","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4161\/cbt.7.5.5689","article-title":"Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia","volume":"7","author":"X Chen","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.4049\/jimmunol.0803831","article-title":"IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients","volume":"182","author":"S Mandruzzato","year":"2009","journal-title":"J Immunol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/j.gastro.2008.03.020","article-title":"A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells","volume":"135","author":"B Hoechst","year":"2008","journal-title":"Gastroenterology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","article-title":"Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy","volume":"58","author":"CM Diaz-Montero","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1158\/1078-0432.CCR-09-3272","article-title":"Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer","volume":"16","author":"S Nagaraj","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/1097-0142(19920815)70:4<733::AID-CNCR2820700403>3.0.CO;2-6","article-title":"Clinical significance of arginase in colorectal cancer","volume":"70","author":"SY Leu","year":"1992","journal-title":"Cancer"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1749-6632.2010.05919.x","article-title":"The role of the PD-1 pathway in autoimmunity and peripheral tolerance","volume":"1217","author":"BT Fife","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"SL Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"JR Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"JR Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","article-title":"Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies","volume":"14","author":"R Berger","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.athoracsur.2010.12.041","article-title":"Clinical significance of the costimulatory molecule B7-H1 in Barrett carcinoma","volume":"91","author":"M Loos","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/ijc.25397","article-title":"PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients","volume":"128","author":"F Shi","year":"2011","journal-title":"Int J Cancer"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1002\/cncr.25747","article-title":"Overall survival and PD-L1 expression in metastasized malignant melanoma","volume":"117","author":"J Gadiot","year":"2011","journal-title":"Cancer"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.exphem.2006.03.006","article-title":"The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans","volume":"34","author":"HR Salih","year":"2006","journal-title":"Exp Hematol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"PD-1 signaling in primary T cells","volume":"229","author":"JL Riley","year":"2009","journal-title":"Immunol Rev"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.4049\/jimmunol.137.12.3841","article-title":"The released interleukin 2 receptor binds interleukin 2 efficiently","volume":"137","author":"LA Rubin","year":"1986","journal-title":"J Immunol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2005.05674.x","article-title":"Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases","volume":"130","author":"KE Panteli","year":"2005","journal-title":"Br J Haematol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood.V74.3.1052.1052","article-title":"Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis","volume":"74","author":"T Motoi","year":"1989","journal-title":"Blood"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/annonc\/3.suppl_4.S49","article-title":"Soluble CD8, CD25 and CD30 antigens as prognostic markers in patients with untreated Hodgkin&apos;s lymphoma","volume":"3 Suppl 4","author":"A Gause","year":"1992","journal-title":"Ann Oncol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0925-5710(96)00554-3","article-title":"Clinical significance of serum soluble interleukin-2 receptor in chronic myeloproliferative disorders","volume":"65","author":"T Kawatani","year":"1997","journal-title":"Int J Hematol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00432-008-0440-0","article-title":"Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)","volume":"135","author":"J Kitagawa","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdn677","article-title":"Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy","volume":"20","author":"D Ennishi","year":"2009","journal-title":"Ann Oncol"},{"key":"ref53","first-page":"961-","article-title":"The Leukemic Stem Cell (LSC) in Ph+ CML Is a CD34+\/CD38\u2212\/Lin- Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1{alpha}","volume":"118","author":"H Herrmann","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"ref54","first-page":"1315","article-title":"Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects","volume":"90","author":"NM Butt","year":"2005","journal-title":"Haematologica"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0055818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T03:12:48Z","timestamp":1688008368000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0055818"}},"subtitle":[],"editor":[{"given":"Gobardhan","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,31]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0055818","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,31]]}}}